Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Jiexin Zhang(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Elsa Li Ning Tapia(The University of Texas MD Anderson Cancer Center), Guanglin Wu(The University of Texas MD Anderson Cancer Center), Sankar N. Maity(The University of Texas MD Anderson Cancer Center), Hsiang-Chun Chen(The University of Texas MD Anderson Cancer Center), Xuemei Wang(The University of Texas MD Anderson Cancer Center), Li Shen(The University of Texas MD Anderson Cancer Center), Jing‐Fang Lu(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Keith Baggerly(The University of Texas MD Anderson Cancer Center), Bradley M. Broom(The University of Texas MD Anderson Cancer Center)
Cited by 297
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k